- Conditions
- Pancreas Cancer, Adenocarcinoma of the Pancreas
- Interventions
- Digoxin, 5Fluorouracil, Calcium Leucovorin, Irinotecan, Oxaliplatin
- Drug
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 107
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Resectable Pancreatic Cancer
- Interventions
- Gemcitabine and Abraxane
- Drug
- Lead sponsor
- Pancreatic Cancer Research Team
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 4
- States / cities
- Scottsdale, Arizona • Grand Rapids, Michigan • Minneapolis, Minnesota + 1 more
- Conditions
- Pancreatic Ductal Adenocarcinoma
- Interventions
- Exercise Program, Nutrition Program
- Behavioral
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Pancreatic Cancer
- Interventions
- Pembrolizumab, Neoadjuvant Chemoradiation
- Drug · Radiation
- Lead sponsor
- Craig L Slingluff, Jr
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • Hartford, Connecticut • Miami, Florida + 3 more
- Conditions
- Pancreatic Cancer
- Interventions
- Capecitabine, Hydroxychloroquine, Proton or Photon Radiation Therapy
- Drug · Radiation
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Pancreatic Cancer
- Interventions
- Tislelizumab, SX-682
- Drug
- Lead sponsor
- Lei Zheng
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • San Antonio, Texas
- Conditions
- Metastatic Pancreatic Adenocarcinoma
- Interventions
- Capecitabine, Oxaliplatin and Irinotecan (CAPOXIRI)
- Drug
- Lead sponsor
- Beth Israel Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 3
- States / cities
- New York, New York
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC), Cancer of Pancreas, Pancreatic Cancer, Adult, Pancreas Adenocarcinoma, Pancreatic Neoplasms, Pancreatic Cancer Non-resectable, Pancreatic Cancer Resectable
- Interventions
- Oxaliplatin, Leucovorin, Irinotecan Hydrochloride, 5-FU
- Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2030
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer
- Interventions
- gemcitabine hydrochloride, hyperfractionated radiation therapy, intensity-modulated radiation therapy, radiosurgery, diffusion-weighted magnetic resonance imaging
- Drug · Radiation · Procedure
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Pancreatic Adenocarcinoma, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Recurrent Pancreatic Carcinoma
- Interventions
- Gemcitabine, Sorafenib, Vorinostat, 3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy, RosetteSep, DEPfff
- Drug · Radiation · Other
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Adenocarcinoma of the Pancreas, Stage III Pancreatic Cancer
- Interventions
- gemcitabine hydrochloride, leucovorin calcium, fluorouracil, nelfinavir mesylate, stereotactic body radiation therapy, hypofractionated radiation therapy, therapeutic conventional surgery
- Drug · Radiation · Procedure
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2015
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Resectable Pancreatic Cancer
- Interventions
- Chemotherapy(FOLFIRINOX) + SBRT prior to surgery if applicable, -Oxaliplatin 85 mg/m2 IV on Day 1, -Irinotecan 180 mg/m2 IV on Day 1, -5-FU (Fluorouracil) 2,400 mg/m2 IV over 46-48 hours
- Other · Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Pancreatic Cancer
- Interventions
- Biopsy, FOLFIRINOX, Ciprofloxacin, Metronidazole, Pembrolizumab, Surgical Resection
- Procedure · Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Pancreatic Cancer
- Interventions
- Neoadjuvant capecitabine, panitumumab and radiation
- Other
- Lead sponsor
- University of Massachusetts, Worcester
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Worcester, Massachusetts
- Conditions
- Pancreatic Cancer
- Interventions
- MKC-1
- Drug
- Lead sponsor
- CASI pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Pancreatic Cancer
- Interventions
- Gemcitabine and Capecitabine
- Drug
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Pancreas Cancer, Localized Pancreas Cancer, Non-metastatic Pancreas Cancer
- Interventions
- FOLFIRINOX Regimen
- Drug
- Lead sponsor
- Baylor Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Resectable Pancreatic Ductal Adenocarcinoma
- Interventions
- FOLFIRINOX
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Pancreatic Cancer Non-resectable
- Interventions
- Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX, Placebo + Gemcitabine + Nab-paclitaxel or Placebo + FOLFIRINOX
- Drug
- Lead sponsor
- Kyntra Bio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 284 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 32
- States / cities
- Phoenix, Arizona • La Jolla, California • Los Angeles, California + 28 more
- Conditions
- Pancreatic Cancer
- Interventions
- Cyclophosphamide, GVAX pancreatic cancer, Nivolumab, Urelumab, BMS-986253
- Drug · Biological
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Ovarian Cancer, Epithelial Ovarian Cancer, Pancreatic Adenocarcinoma
- Interventions
- Prehabilitation
- Other
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Pancreatic Cancer
- Interventions
- Proton Beam Radiation, Capecitabine
- Procedure · Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2017
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Pancreatic Ductal Adenocarcinoma
- Interventions
- ASP2138, Oxaliplatin, Leucovorin, 5-FU, Irinotecan, Gemcitabine, Nab-paclitaxel, Capecitabine
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • New York, New York • Durham, North Carolina
- Conditions
- Pancreatic Cancer
- Interventions
- First-line Chemotherapy, Second-line Chemotherapy, Chemoradiation
- Drug · Radiation
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2032
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin